<DOC>
	<DOCNO>NCT02921685</DOCNO>
	<brief_summary>This study determine Maximal Tolerated Dose recommend dose phase 2 monalizumab , monoclonal antibody direct CD94/NKG2A receptor , allogenic stem cell transplantation . All patient receive one single intravenous administration one four dos monalizumab .</brief_summary>
	<brief_title>Study Humanized Antibody Initiated 2 Months After HLA Matched Allogenic Stem Cell Transplantation</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( Allo-HSCT ) curative option hematological malignancy , though graft-versus-tumor ( GVT ) effect mediate immune cell donor . However , use Allo-HSCT limited toxicity , notably graft-versus-host disease ( GVHD ) major cause non-relapse mortality ( NRM ) . Conditioning regimen dramatically improve last fifteen year , decrease GVHD NRM rate . Now , disease recurrence Allo-HSCT first cause treatment failure remain concern approximately 30 % patient . Based safety immunologic platform ( ATG base reduce toxicity conditioning regimen ) , need develop post Allo-HSCT strategy decrease incidence relapse . In context , modulation immune cell activity could play role prevent relapse . NK cell unique capacity exert potent GVT effect without induce GVHD . Moreover , NK cell recovery occur early Allo-HSCT NK cell function severely impaired use ciclosporin A , give month Allo-HSCT GVHD prophylaxis . Thus , NK cell modulation appear viable option early immune intervention Allo-HSCT . Monalizumab ( IPH2201 ) , monoclonal antibody non-depleting purely block activity direct high affinity specificity CD94/NKG2A receptor express subset NK cell , activate αβ CD8+ T cell , γδ-T cell NK T cell . By suppress inhibitory signal transduce NKG2A , IPH2201 enhance anti-tumor function , include cytolytic activity immune effector cells.The aim study determine safety IPH2201 allogenic stem cell transplantation .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Patients present hematological malignancy ( acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome , multiple myeloma , chronic lymphoid leukemia , chronic myeloid leukemia , myeloproliferative neoplasm , Hodgkin lymphoma NonHodgkin lymphoma ) treat allogeneic HSCT accord follow parameter : Donor : HLA match relate unrelated ( 10/10 ) donor Graft : peripheral blood stem cell Conditioning : All type condition reduce toxicity conditioning regimens ATG invivo Tcell depletion GVHD prophylaxis cyclosporine , still ongoing full dose time inclusion 2 . Patient one follow postgraft situation time inclusion : Acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) patient : morphological complete remission ( CR ) less 5 % bone marrow blast count . Highrisk RIPSS myelodysplastic syndrome patient : least marrow CR le 5 % marrow blast count . Multiple myeloma patient : least good partial response . Chronic Lymphoid Leukemia patient : CR . Chronic Myeloid Leukemia patient : hematological CR . Myeloproliferative neoplasm patient : criterion disease acceleration phase . Hodgkin lymphoma NonHodgkin lymphoma patient : CR . 3 . Age ≥ 18 ≤ 70 year 4 . ECOG = 01 Karnofsky index ≥ 70 % 5 . Clinical laboratory value screen Calculated creatinine clearance ( accord MDRD ) &gt; 50 ml/min/1.73 m2 Independence red blood cell transfusion Platelet count &gt; 75 x 109/l ANC &gt; 1 x 109/l Bilirubin &lt; 1.5 ULN ALT AST &lt; 3 ULN 6 . Patients ( male female ) accept able use contraception method recognize highly effective throughout study 5 month drug administration 7 . Signed informed consent current clinical study , prior protocolspecific procedure 8 . Patient affiliate national `` Social Security '' regimen beneficiary regimen Non inclusion Criteria : 1 . Previous history grade ≥ 2 acute GVHD 2 . Current active disease positive serology HIV , and/or HCV detectable viremia and/or HBV positive Hbs Antigen . 3 . Abnormal cardiac status follow : Ejection fraction ( measure ultrasound radionuclide image ) &lt; 50 % Unstable angina Myocardial infarction within last 6 month Presence persistence document congestive heart failure ( New York Heart Association functional classification IIIIV ) Arrhythmia require treatment stabilize treatment . QTc ≥ 450 m ( M ) 470 m ( F ) ( Bazett formula ) 4 . Previous allogeneic hematopoietic transplantation solid organ transplantation 5 . Any serious concurrent uncontrolled medical disorder within 4 week prior IPH2201 administration 6 . Use systemic corticosteroid ongoing within last 4 week 7 . Use investigational agent within 3 month prior first dose 8 . History another malignancy ( except basal cell carcinoma skin , situ cervix carcinoma , malignancy complete remission 3 year since completion treatment ) . However case leukemia MDS previous malignancy accountable present disease exclusion criterion complete remission 2 year 9 . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule 10 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>